Makena Resources Inc., Biocan Technologies Inc. and Epimeron Inc. Announce Completion of Private Placement, Strategic Investment From Tuatara Capital and Business Combination to Form Willow Biosciences Inc.

VANCOUVER and CALGARY, April 12, 2019 /CNW/ – Makena Resources Inc. (“Makena“) (CSE: MKNA), BioCan Technologies Inc. (“BioCan“) and Epimeron Inc. (“Epimeron“) are pleased to announce: (i) the completion of the previously announced non-brokered private placement of common shares (“Common Shares“) and units (“Units“) of Makena for aggregate gross proceeds of $29.0 million (the “Private Placement“), including an investment of $12.1 million of Units by Tuatara Capital, L.P. (“Tuatara“), a sector-focused cannabis private equity firm; (ii) the completion of the previously announced business combination by way of a statutory plan of arrangement (the “Arrangement“) involving Makena, BioCan and Epimeron under the Business Corporations Act (Alberta); (iii) the name change of Makena to “Willow Biosciences Inc.” (“Willow“); and (iv) the appointment of a new management team (the “New Management Team“) and board of directors (the “New Board“) of Willow.

The Common Shares will commence trading on the Canadian Securities Exchange (the “CSE“) under the new name “Willow Biosciences Inc.” and new trading symbol “WLLW” at the market opening on Monday, April 15, 2019.

Willow Highlights

  • With a net working capital position of approximately $27.5 million(1), Willow is well-positioned to become an industry leader in cannabinoid biosynthetic production by capturing key intellectual property around the most cost effective methods to produce cannabinoids;
  • The combination of Makena, BioCan and Epimeron will drive greater operational capacity, exposure to Canadian and U.S. markets, a larger market capitalization and natural synergies between BioCan and Epimeron to expand BioCan’s current biosynthesis platform; and
  • The Arrangement brings together world-leading discovery biologists and business experts in Canada and the United States who will guide a multidisciplinary team that possesses the capabilities needed to underpin achievement at all stages of the development cycle (from gene discovery through manufacturing and commercialization).

Note:

1) After giving effect the Arrangement and the Private Placement, as well as certain adjustments, including transaction costs.

Trevor Peters, President and Chief Executive Officer of Willow, commented: “We are very excited to be entering our next phase of development. The capital we have raised will augment and accelerate the work we have already started in developing a biosynthesis platform for producing cannabinoids and will fund us to full scale production”.

Private Placement

Pursuant to the Private Placement, Makena issued an aggregate of 828,571,429 Common Shares and Units at a price of $0.035 per Common Share or Unit, as applicable, for aggregate gross proceeds of $29.0 million, representing an upsize of $0.5 million from the previous announcement. Units were issued to subscribers that are members of the New Management Team and New Board, together with certain additional subscribers identified by such persons, and Common Shares were issued to all other subscribers. Each Unit is comprised of one Common Share and one performance-based Common Share purchase warrant (each, a “Performance Warrant“). Subject to the certificates representing the Performance Warrants, each Performance Warrant entitles the holder to purchase one Common Share at a price of $0.035 for a period of five years. The Performance Warrants will vest and become exercisable as to: (i) one-third upon the 20-day volume weighted average trading price of the Common Shares (the “Market Price“) equaling or exceeding $0.0525; (ii) an additional one-third upon the Market Price equaling or exceeding $0.070; and (iii) a final one-third upon the Market Price equaling or exceeding $0.0875. In addition, in the event the Market Price equals or exceeds $0.140, each Performance Warrant will be exercisable for 1.5 Common Shares, provided that, at the time of exercise in respect of the additional 0.5 of a Common Share per Performance Warrant, the Common Shares are: (i) listed on the facilities of a recognized stock exchange (other than the CSE or the TSX Venture Exchange (the “TSXV“)); (ii) acquired for cash; or (iii) acquired for the securities of a company listed on a recognized stock exchange (other than the CSE or the TSXV).

Pursuant to applicable securities laws, all securities issued pursuant to the Private Placement will be subject to a hold period of four months plus one day following the date of issuance of such securities.

The New Management Team intends to use the net proceeds from the Private Placement to fund the pro forma business plan of Willow and for working capital and general corporate purposes.

As a result of the Private Placement, Tuatara became a new “control person” of Willow, as such term is defined by the policies of the CSE.

Arrangement

Pursuant to the Arrangement: (i) each outstanding common share of BioCan was exchanged for 7.301 Common Shares; and (ii) each outstanding common share of Epimeron was exchanged for 577.153 Common Shares, through the issuance of an aggregate of 857,142,858 Common Shares on the basis of a deemed value of $0.035 per Common Share for a total transaction value of $30.0 million.

In connection with the Arrangement, Makena sold all of its mining assets to an arm’s length third party.

Following completion of the transactions, Willow has a total of 1,731,328,462 Common Shares and 543,525,321 Performance Warrants issued and outstanding.

Eight Capital acted as financial advisor in respect of the Arrangement and the Private Placement, including the investment by Tuatara. AltaCorp Capital Inc. and Laurentian Bank Securities Inc. acted as strategic advisors in respect of the Private Placement.

New Management Team and Board of Directors

Willow’s New Management Team and New Board include the following individuals:

Trevor Peters
Director, President and Chief Executive Officer

Dr. Joseph Tucker
Executive Chairman

Dr. Peter Facchini
Chief Scientific Officer

Travis Doupe
Chief Financial Officer

Jerry Ericsson
Vice President, Operations

Dr. Jillian Hagel
Vice President, Applied Science

Dr. Mathias Schuetz
Vice President, Research and Development

Sanjib (Sony) Gill
Corporate Secretary

Dr. Peter Seufer-Wasserthal
Director

Sadiq H. Lalani
Director

Donald Archibald
Director

Dr. Fotis Kalantzis
Director

Al Foreman
Director

About Tuatara Capital, L.P.

Tuatara Capital, L.P. is a specialized alternative investment manager founded in 2014 to support the legal cannabis industry. Tuatara currently manages over $285 million in cannabis-focused assets and invests in market-leading companies that are well-positioned to benefit from the long-term growth trends of legalized cannabis. Tuatara’s investment philosophy revolves around partnership with innovative entrepreneurs and great management teams to help build high-growth companies. Tuatara applies strategic insights, financial experience and a network of relationships to support its portfolio companies in building industry-leading brands and businesses that will help to shape the future of the legal cannabis industry For more information about Tuatara please visit: www.tuataracapital.com.

Additional Information

Please refer to the listing statement of Makena dated April 12, 2019 for additional information regarding Willow, Makena, BioCan, Epimeron, the Arrangement and the Financing, which will be available under Willow’s profile on www.sedar.com upon trading on Monday, April 15, 2019.

For further information, please contact:

Trevor Peters
President and Chief Executive Officer
T: (403) 669-4848
E: t.peters@willowbio.com

Troy Talkkari
CFA Vice President, Corporate Development
T: (403) 618-1117
E: t.talkkari@willowbio.com

3655 36th Street NW
Calgary, AB T2R 0Y6

Reader Advisory

Investors are cautioned that, except as disclosed in the listing statement prepared in connection with the Arrangement, any information released or received with respect to the Arrangement and the Private Placement may not be accurate or complete and should not be relied upon. Trading in the securities of Willow should be considered highly speculative.

This press release is not an offer of the securities for sale in the United States. The securities may not be offered or sold in the United States absent registration or an available exemption from the registration requirements of the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”) and applicable U.S. state securities laws. Makena will not make any public offering of the securities in the United States. The securities have not been and will not be registered under the U.S. Securities Act.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful.

The Canadian Securities Exchange has in no way passed upon the merits of the Arrangement or the Private Placement and has neither approved nor disapproved of the contents of this press release.

Neither the Canadian Securities Exchange nor the Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words “expect”, “anticipate”, “continue”, “estimate”, “objective”, “ongoing”, “may”, “will”, “project”, “should”, “believe”, “plans”, “intends” and similar expressions are intended to identify forward-looking information or statements. More particularly, and without limitation, this news release contains forward looking statements and information concerning Willow’s business, strategies, expectations, planned operations or future actions and the anticipated benefits of the Arrangement and the Private Placement.

The forward-looking statements and information are based on certain key expectations and assumptions made by Makena, BioCan and Epimeron, including expectations and assumptions concerning: Makena, BioCan, Epimeron and Willow; the Arrangement and the Private Placement; the future operations of, and transactions completed by, Willow; the availability of sufficient capital; the availability of and access to qualified personnel; Willow’s ability to protect its intellectual property; the expected growth in the cannabis market, including demand for cultured cannabinoids; expectations regarding the regulatory framework for cultured cannabinoids; the medical benefits, viability, safety, efficacy, dosing and social acceptance of cannabis; the securities markets and the general economy; the legalization of the use of cannabis for medical and/or adult use in jurisdictions outside of Canada; and applicable laws not changing in a manner that is unfavorable to Willow.

Although Makena, BioCan and Epimeron believe that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward looking statements and information because Makena, BioCan and Epimeron can give no assurance that they will prove to be correct. By its nature, such forward-looking information is subject to various risks and uncertainties, which could cause the actual results and expectations to differ materially from the anticipated results or expectations expressed. Without limitation, these risks and uncertainties include: risks associated with the cannabis industry in general, infringement on intellectual property, failure to benefit from partnerships or successfully integrate acquisitions, actions and initiatives of federal and provincial governments and changes to government policies and the execution and impact of these actions, initiatives and policies, import/export and research restrictions for cannabinoid-based operations, the size of the medical-use and adult-use cannabis market, competition from other industry participants, adverse U.S., Canadian and global economic conditions, failure to comply with certain regulations and departure of key management personnel or inability to attract and retain talent. Makena, BioCan and Epimeron undertake no obligation to update publicly or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.

News

Latest news, media & events

28/03/2024

WILLOW BIOSCIENCES REPORTS FOURTH QUARTER AND FISCAL YEAR 2023 FINANCIALS AND OPERATIONS AND FILING OF ITS 2023 AIF

Completed the reorganization of the Company during 2023 with all lab operations now located...
20/02/2024

WILLOW BIOSCIENCES ANNOUNCES STRATEGIC INVESTMENT FROM KALSEC TO DEVELOP INNOVATIVE NATURAL FOOD INGREDIENTS

Investment further validates Willow’s technology for the development and sustainable manufacture of natural ingredients...
31/01/2024

WILLOW ANNOUNCES COLLABORATION WITH GLOBAL INGREDIENT MANUFACTURER TO DEVELOP A MORE COST-EFFECTIVE, SUSTAINABLE PROCESS FOR A LARGE VOLUME ACTIVE PHARMACEUTICAL INGREDIENT

Sunnyvale, California – January 31, 2024 – Willow Biosciences Inc. ("Willow") (TSX: WLLW) (OTCQB: CANSF), a...
16/01/2024

WILLOW ANNOUNCES COLLABORATION WITH ENTERIN TO DEVELOP SUSTAINABLE INTERMEDIATES AND ACTIVE PHARMACEUTICAL INGREDIENTS

Sunnyvale, California – January 16, 2024 – Willow Biosciences Inc. ("Willow") (TSX: WLLW) (OTCQB: CANSF), a...
10/01/2024

WILLOW PLANS FOR SIGNIFICANT GROWTH IN 2024 ON THE BACK OF A SUCCESSFUL 2023

Estimated FY 2023 revenues in excess of $1.3 million is a record year for...
07/12/2023

WILLOW AND LEADING INNOVATIVE BIOPHARMACEUTICAL COMPANY ADVANCE DEVELOPMENT PROGRAM TO MANUFACTURE SUSTAINABLE INTERMEDIATES AND ACTIVE PHARMACEUTICAL INGREDIENTS

Program brings immediate R&D revenue and first commercial supply revenue as early as 2024...
21/11/2023

WILLOW BIOSCIENCES REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Record revenues for the third quarter and the nine months ended September 30, 2023...
11/10/2023

WILLOW BIOSCIENCES ANNOUNCES COMPLETION OF PREVIOUSLY ANNOUNCED CONVERTIBLE DEBENTURE FINANCING

Calgary, Alberta – October 10, 2023 – Willow Biosciences Inc.("Willow" or the "Company") (TSX: WLLW; OTCQB: CANSF),...
03/10/2023

WILLOW AND SUANFARMA ANNOUNCE COLLABORATION ON DEVELOPMENT OF LARGE VOLUME ANTI-INFECTIVE API THROUGH PRECISION FERMENTATION

Sunnyvale, California  ̶  October 3, 2023  ̶ Willow Biosciences Inc., (“Willow”) (TSX: WLLW) (OTCQB:...
12/09/2023

WILLOW BIOSCIENCES ANNOUNCES COMPANY INSIDER LED CONVERTIBLE DEBENTURE FINANCING

Calgary, Alberta – September 12, 2023 – Willow Biosciences Inc.("Willow" or the "Company") (TSX: WLLW; OTCQB: CANSF),...
06/09/2023

WILLOW ANNOUNCES SUCCESSFUL COMPLETION OF R&D PROGRAM ON COST-EFFECTIVE, SUSTAINABLY PRODUCED UDCA

Company's BioOxi™ Platform solves for selective C-H hydroxylation, one of the "Holy Grails" of...
02/09/2023

WILLOW ANNOUNCES FILING OF PATENT APPLICATION FOR PROCESS TO PRODUCE CORTICOSTEROIDS AT SIGNFICANTLY REDUCED COST

Company's BioOxi™-based process reduces number of steps and associated costs of corticosteroids manufacturing by...
24/08/2023

WILLOW BIOSCIENCES ANNOUNCES COMMERCIAL TRANSITION AND FOCUS ON BIOOXI PLATFORM

Announces commercial focus on BioOxiTM bio-oxidation platform as part of targeted alignment on nearer-term and...
21/08/2023

WILLOW ANNOUNCES COLLABORATION WITH A LEADING INNOVATIVE BIOPHARMACEUTICAL COMPANY TO DEVELOP SUSTAINABLE INTERMEDIATES AND ACTIVE PHARMACEUTICAL INGREDIENTS

Sunnyvale, California – August 21, 2023 – Willow Biosciences Inc. ("Willow") (TSX: WLLW) (OTCQB: CANSF), a...
08/08/2023

WILLOW BIOSCIENCES REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS

New partnerships and contracts expected to bring in $1 million in near-term R&D/milestone revenue...
02/08/2023

WILLOW BIOSCIENCES TO PRESENT AT THE EMERGING GROWTH CONFERENCE ON AUGUST 9

President and CEO Dr. Chris Savile to provide business update at event open to...
20/07/2023

WILLOW AND KALSEC ADVANCE DEVELOPMENT PROGRAM FOR NEW NATURAL FUNCTIONAL INGREDIENT FOR SAVORY FOODS

Program further validates Willow’s technology and focus on commercial execution and aligns with its...
07/06/2023

WILLOW BIOSCIENCES TO PRESENT AT THE EMERGING GROWTH CONFERENCE ON JUNE 14

President and CEO Dr. Chris Savile to provide business update at event open to...
31/05/2023

WILLOW SIGNS MASTER SERVICES AGREEMENT WITH INNOVATIVE BIOTECH COMPANY TO DEVELOP INGREDIENTS FOR AGE-RELATED DISEASES

Biotech partner recognizes strength of Willow’s first in class FutureGrownTM technology platform for producing...
23/05/2023

KALSEC AND WILLOW BIOSCIENCES TO DEVELOP NOVEL ENZYME FOR PRODUCTION OF AN ADVANCED BEVERAGE INGREDIENT

Rapid success of first collaboration leads to partnership on high-value specialty ingredient Enzyme development...
15/05/2023

WILLOW BIOSCIENCES ANNOUNCESANNUAL GENERAL AND SPECIAL MEETING VOTING RESULTS

Mountain View, California – May 12, 2023 – Willow Biosciences Inc.("Willow" or the "Company")...
12/05/2023

WILLOW BIOSCIENCES REPORTS FIRST QUARTER 2023 RESULTS

Starts off year with significant commercial momentum toward focus on delivering robust year-over-year revenue...
18/04/2023

WILLOW ANNOUNCES COMMERCIAL AGREEMENT WITH SANDHILL ONE

Commercial agreement follows the early success on the development phase of the UDCA program...
12/04/2023

WILLOW ANNOUNCES ROLLOUT OF BioOxi PLATFORM PROVIDING VALUABLE AND EXPEDITED BIOCONVERSION-ENABLED CHEMICAL MANUFACTURING

Complements Company’s significant expertise in existing strain engineering and  precision fermentation Offers commercial partners...
28/03/2023

WILLOW BIOSCIENCES ANNOUNCES CHANGES TO BOARD AND MANAGEMENT

Willow Continues its Transition to the Bay Area in California with Management Promotions and...
22/03/2023

WILLOW & SUANFARMA ANNOUNCE COMPLETED DEVELOPMENT AND MANUFACTURING PROCESS FOR CBG AND COMMITMENT TO THE PRODUCTION OF NEW MOLECULES IN A NATURAL WAY

Calgary, Alberta and Mountain View, California March 22, 2023 - WILLOW BIOSCIENCES, (TSX: WLLW)...
22/03/2023

WILLOW BIOSCIENCES REPORTS FOURTH QUARTER AND FISCAL YEAR 2022 FINANCIALS AND OPERATIONS AND FILING OF ITS 2022 AIF

Reports Highest Quarterly and Annual Revenue in Company History with Significant Year-Over-Year Growth Expected...
22/02/2023

WILLOW ANNOUNCES APPOINTMENT OF DR. JIM LALONDE TO BOARD OF DIRECTORS

Dr. Lalonde has pioneered key advancements in enzyme engineering and biocatalysis that has revolutionized...
17/01/2023

WILLOW ANNOUNCES FOLLOW-ON ENGAGEMENT FOR NEXT PHASE OF PARTNERED PHARMACEUTICAL PROJECT

Represents early progress against targeted milestones anticipated for 2023 to expand company growth Calgary,...
14/12/2022

WILLOW PROVIDES CORPORATE UPDATES, BUSINESS OUTLOOK AND KEY TARGETED MILESTONES ANTICIPATED FOR 2023 TO EXPAND GROWTH

Calgary, Alberta and Mountain View, California – December 14, 2022 – Willow Biosciences Inc.("Willow"...
07/12/2022

WILLOW FURTHER OPTIMIZES ITS BUSINESS TO FOCUS ON NEAR-TERM REVENUE GENERATION AND REDUCE CASH BURN

Calgary, Alberta and Mountain View, California – December 7, 2022 – Willow Biosciences Inc.("Willow")...
08/11/2022

KALSEC SIGNS MASTER SERVICES AGREEMENT WITH WILLOW BIOSCIENCES FOR THE DEVELOPMENT AND MANUFACTURE OF FUNCTIONAL FOOD INGREDIENTS USING PRECISION FERMENTATION

Kalamazoo, Michigan, Calgary, Alberta and Mountain View, California – November 8, 2022 – Willow Biosciences...
07/11/2022

WILLOW BIOSCIENCES TO HOST INVESTOR PRESENTATION WEBCAST

Calgary, Alberta and Mountain View, California – November 7, 2022 – Willow Biosciences Inc. ("Willow" or...
03/11/2022

WILLOW BIOSCIENCES REPORTS THIRD QUARTER 2022 RESULTS AND ANNOUNCES APPOINTMENT OF DR SEUFER-WASSERTHAL AS PRESIDENT AND CEO

Calgary, Alberta and Mountain View, California – November 3, 2022 – Willow Biosciences Inc. ("Willow" or...
12/10/2022

WILLOW BIOSCIENCES ANNOUNCES NEW FUNCTIONAL INGREDIENT ASTAXANTHIN ADDED TO PRODUCT PORTFOLIO

Calgary, Alberta and Mountain View, California – October 12, 2022 – Willow Biosciences Inc. ("Willow" or...
31/08/2022

WILLOW BIOSCIENCES PROVIDES CBG UPDATE

Calgary, Alberta and Mountain View, California – August 31, 2022 – Willow Biosciences Inc. ("Willow"...
15/08/2022

WILLOW BIOSCIENCES REPORTS SECOND QUARTER 2022 RESULTS

Calgary, Alberta and Mountain View, California – August 15, 2022 – Willow Biosciences Inc. ("Willow" or...
18/07/2022

WILLOW BIOSCIENCES APPOINTS DR. PETER SEUFER-WASSERTHAL AS INTERIM PRESIDENT AND CEO

Calgary, Alberta and Mountain View, California – July 18, 2022 – Willow Biosciences Inc. ("Willow" or...
06/06/2022

WILLOW BIOSCIENCES INCORPORATES INSCRIPTA’S ONYX® PLATFORM TO EXPAND STRAIN ENGINEERING CAPABILITIES AND THROUGHPUT

Calgary, Alberta and Mountain View, California – June 6, 2022 – Willow Biosciences Inc. ("Willow" or...
31/05/2022

WILLOW BIOSCIENCES EXPANDS ITS PORTFOLIO WITH A NEW PARTNERED PHARMACEUTICAL PROJECT

Calgary, Alberta and Mountain View, California – May 31, 2022 – Willow Biosciences Inc. ("Willow"...
12/05/2022

WILLOW BIOSCIENCES REPORTS FIRST QUARTER 2022 RESULTS

Vancouver, British Columbia – May 12, 2022 – Willow Biosciences Inc. ("Willow" or the "Company")...
11/05/2022

WILLOW BIOSCIENCES ANNOUNCES EXPANSION OF ITS FERMENTATION MANUFACTURING NETWORK AND PROGRESS ON ITS CBG GRAS DETERMINATION

Vancouver, British Columbia – May 11, 2022 – Willow Biosciences Inc. ("Willow" or the "Company")...
30/03/2022

WILLOW BIOSCIENCES REPORTS FOURTH QUARTER AND 2021 YEAR END RESULTS, FILING OF ITS 2021 AIF, AND OPERATIONAL UPDATE

Vancouver, British Columbia – March 29, 2022 – Willow Biosciences Inc. ("Willow" or the "Company")...
31/01/2022

WILLOW BIOSCIENCES TO HOST INVESTOR PRESENTATION WEBCAST

Vancouver, British Columbia – January 31, 2022 – Willow Biosciences Inc. ("Willow" or the "Company")...
19/01/2022

WILLOW BIOSCIENCES PUBLISHES THE FIRST PEER REVIEWED ARTICLE DEMONSTRATING THE CLINICAL BENEFIT OF CBG FOR SKINCARE

Vancouver, British Columbia – January 19, 2022 – Willow Biosciences Inc. ("Willow" or the "Company")...
15/11/2021

WILLOW BIOSCIENCES REPORTS THIRD QUARTER 2021 RESULTS

Vancouver, British Columbia – November 15, 2021 – Willow Biosciences Inc. ("Willow" or the "Company")...
21/09/2021

WILLOW BIOSCIENCES ANNOUNCES COMMERCIAL SCALE OPERATIONAL UPDATE, CBGA PRODUCTION UPDATE AND CORPORATE UPDATE

Vancouver, British Columbia – September 21, 2021 – Willow Biosciences Inc. ("Willow" or the "Company")...
09/08/2021

WILLOW BIOSCIENCES REPORTS SECOND QUARTER 2021 RESULTS

Vancouver, British Columbia – August 9, 2021 – Willow Biosciences Inc. ("Willow" or the "Company")...
20/07/2021

WILLOW BIOSCIENCES ANNOUNCES EXPANSION OF ITS COMMERCIAL OPERATIONS TEAM AND DEVELOPMENT PORTFOLIO, AN UPDATE ON ITS INTELLECTUAL PROPERTY POSITION, AND FORMATION OF ESG COMMITTEE

ancouver, British Columbia – July 20, 2021 – Willow Biosciences Inc. ("Willow" or the "Company")...
10/06/2021

WILLOW BIOSCIENCES AND CELLULAR GOODS ANNOUNCE MULTIYEAR SUPPLY AGREEMENT FOR CANNABIGEROL (CBG)

Vancouver, British Columbia – June 10, 2021 – Willow Biosciences Inc. ("Willow" or the "Company")...
25/05/2021

WILLOW BIOSCIENCES ANNOUNCES PARTICIPATION IN SYNBIOBETA PANEL DISCUSSION

Vancouver, British Columbia – May 25, 2021 – Willow Biosciences Inc. ("Willow" or the "Company")...
18/05/2021

WILLOW BIOSCIENCES ADDED TO NYSE-LISTED CANNABIS ETF “THCX”

Vancouver, British Columbia – May 18, 2021 – Willow Biosciences Inc. ("Willow" or the "Company")...
07/05/2021

WILLOW BIOSCIENCES REPORTS FIRST QUARTER 2021 RESULTS, AN OPERATIONAL UPDATE AND THE ADDITION OF A NEW BOARD MEMBER

Vancouver, British Columbia – May 7, 2021 – Willow Biosciences Inc. ("Willow" or the "Company")...
28/04/2021

WILLOW BIOSCIENCES ANNOUNCES ANNUAL GENERAL AND SPECIAL MEETING VOTING RESULTS

Vancouver, British Columbia – April 28, 2021 – Willow Biosciences Inc. ("Willow" or "the Company")...
20/04/2021

WILLOW BIOSCIENCES ANNOUNCES GROUND-BREAKING SCIENTIFIC DATA FOR CANNABIGEROL (CBG) ON HUMAN SKIN

Vancouver, British Columbia – April 20, 2021 – Willow Biosciences Inc. ("Willow" or the "Company")...
31/03/2021

WILLOW BIOSCIENCES ANNOUNCES COMPLETION OF ITS FIRST COMMERCIAL SCALE FERMENTATION RUN

Vancouver, British Columbia – March 31, 2021 – Willow Biosciences Inc. ("Willow" or the "Company")...
24/03/2021

WILLOW BIOSCIENCES REPORTS FOURTH QUARTER AND 2020 YEAR END RESULTS AND OPERATIONAL UPDATE

Calgary, Alberta – March 23, 2021 – Willow Biosciences Inc. ("Willow" or the "Company") (TSX:...
03/03/2021

WILLOW BIOSCIENCES PROVIDES UPDATE ON ACCELERATION OF EXPIRY DATE OF OUTSTANDING WARRANTS ISSUED PURSUANT TO OCTOBER 2020 UNIT FINANCING

Vancouver, British Columbia – March 3, 2021 – Willow Biosciences Inc. ("Willow" or the "Company")...
19/02/2021

WILLOW BIOSCIENCES ANNOUNCES EXERCISE OF OVER-ALLOTMENT OPTION AND COMPLETION OF PREVIOUSLY ANNOUNCED BOUGHT DEAL OFFERING

Vancouver, British Columbia – February 19, 2021 – Willow Biosciences Inc. ("Willow" or the "Company")...
11/02/2021

WILLOW BIOSCIENCES ANNOUNCES INCREASE TO BOUGHT DEAL OFFERING FROM $20.0 MILLION TO $25.0 MILLION

Vancouver, British Columbia – Feb. 11, 2021 – Willow Biosciences Inc. ("Willow" or the "Company")...
26/01/2021

WILLOW BIOSCIENCES ANNOUNCES ACCELERATION OF EXPIRY DATE OF OUTSTANDING WARRANTS ISSUED PURSUANT TO OCTOBER 2020 UNIT FINANCING

Vancouver, British Columbia – January 25, 2021 – Willow Biosciences Inc. ("Willow" or the "Company")...
19/01/2021

WILLOW BIOSCIENCES ADVANCES ITS WORK ON THC; PLANS TO LAUNCH IN THE CANADIAN MARKET

Vancouver, British Columbia – January 19, 2021 – Willow Biosciences Inc. ("Willow" or the "Company")...
13/01/2021

WILLOW BIOSCIENCES PROVIDES UPDATE ON CANNABIGEROL RESEARCH STUDIES AND KEY PERSONNEL APPOINTMENT

Vancouver, British Columbia – January 13, 2021 – Willow Biosciences Inc. ("Willow" or the "Company")...
16/12/2020

WILLOW BIOSCIENCES ADVANCES ITS COMMERICALIZATION PLAN; FIRST COMMERCIAL PRODUCTION EXPECTED IN EARLY 2021

Leading manufacturer contracted for commercial cannabinoid production • First commercial quantities of ultra-pure CBG...
13/11/2020

WILLOW BIOSCIENCES REPORTS THIRD QUARTER 2020 RESULTS AND OPERATIONAL UPDATE

Calgary, Alberta – November 12, 2020 – Willow Biosciences Inc. ("Willow" or the "Company") (TSX:...
21/10/2020

WILLOW BIOSCIENCES ANNOUNCES PRICING AND UPSIZE OF PREVIOUSLY ANNOUNCED PUBLIC OFFERING TO $10.0 MILLION

Vancouver, British Columbia – October 21, 2020 – Willow Biosciences Inc. ("Willow" or the "Company")...
20/10/2020

WILLOW BIOSCIENCES ANNOUNCES OVERNIGHT MARKETED PUBLIC OFFERING FOR PROCEEDS OF APPROXIMATELY $8.0 MILLION

Vancouver, British Columbia – October 20, 2020 – Willow Biosciences Inc. ("Willow" or the "Company")...
08/10/2020

WILLOW BIOSCIENCES PARTNERS WITH RESEARCHERS AT THE UNIVERSITY OF LETHBRIDGE AND UNIVERSITY OF CALGARY TO STUDY EFFECTS OF NON-PSYCHOACTIVE CANNABINOIDS ON PAIN, INFLAMMATION AND DEPRESSION

Vancouver, British Columbia – October 8, 2020 – Willow Biosciences Inc. ("Willow" or the "Company")...
21/09/2020

WILLOW BIOSCIENCES ANNOUNCES SUCCESSFUL PRODUCTION OF PURE CANNABIGEROL

Vancouver, British Columbia – Sept 21, 2020 – Willow Biosciences Inc. ("Willow" or the "Company")...
08/09/2020

WILLOW BIOSCIENCES ANNOUNCES RESEARCH AND DEVELOPMENT FUNDING FOR ITS VARIN CANNABINOIDS

Vancouver, British Columbia – September 8, 2020 – Willow Biosciences Inc. ("Willow" or the "Company")...
12/08/2020

WILLOW BIOSCIENCES REPORTS SECOND QUARTER 2020 RESULTS AND OPERATIONAL UPDATE

Calgary, Alberta – August 12, 2020 – Willow Biosciences Inc. ("Willow" or the "Company") (TSX:...
29/07/2020

WILLOW BIOSCIENCES ANNOUNCES IT HAS COMMENCED ITS PILOT TO PRODUCE ITS FIRST CANNABINOID

Vancouver, British Columbia – July 29, 2020 – Willow Biosciences Inc. ("Willow" or the "Company")...
06/07/2020

Willow Biosciences Inc. to Webcast Live at VirtualInvestorConferences.com July 9th

Company invites individual and institutional investors, as well as advisors and analysts, to attend...
22/06/2020

WILLOW BIOSCIENCES ANNOUNCES APPOINTMENT OF SENIOR VICE PRESIDENT, SALES AND MARKETING

Calgary, Alberta – June 22, 2020 – Willow Biosciences Inc. ("Willow" or the "Company") (TSX:...
17/06/2020

WILLOW BIOSCIENCES ANNOUNCES EXPEDITED PILOT PRODUCTION AND ADDS MULTIPLE NEW CANNABINOIDS TO PORTFOLIO

Calgary, Alberta – June 17, 2020 – Willow Biosciences Inc. ("Willow" or the "Company") (TSX:...
14/05/2020

Willow Biosciences Reports First Quarter 2020 Results and Provides Operations Update

Calgary, Alberta – May 14, 2020 – Willow Biosciences Inc. ("Willow" or the "Company") (TSX:...
09/04/2020

Willow Biosciences Announces Changes To Its Management Team

Calgary, Alberta – April 7, 2020 – Willow Biosciences Inc. ("Willow" or the "Company")...
24/03/2020

Willow Biosciences Reports Fourth Quarter And 2019 Year End Results And Operational Update

Calgary, Alberta – March 24, 2020 – Willow Biosciences Inc. ("Willow" or the "Company")...
12/03/2020

Willow Biosciences Announces Cannabinoid Scale-up And Expedited Path To Commercialization

Calgary, Alberta – March 12, 2020 – Willow Biosciences Inc. ("Willow" or the "Company")...
07/02/2020

Willow Biosciences Improves Governance With Appointment Of Independent Chairman

Calgary, Alberta – February 7, 2020 – Willow Biosciences Inc. ("Willow" or the "Company")...
03/12/2019

Willow Biosciences Comments on Descheduling of Partner’s Cannabidiol by U.S. Drug Enforcement Agency

Calgary, Alberta, December 3, 2019 – Willow Biosciences Inc.("Willow" or the "Company") (CSE: WLLW; OTCQB: CANSF),...
25/11/2019

Willow Biosciences Receives Conditional Approval to List on the Toronto Stock Exchange

CALGARY, November 25, 2019 – Willow Biosciences Inc. (“Willow” or the “Company“) (CSE: WLLW;...
21/11/2019

Willow Biosciences Reports Third Quarter 2019 Results and Provides Operations Update

CALGARY, Nov. 21, 2019 /CNW/ – Willow Biosciences Inc. (“Willow” or the “Company“) (CSE:...
05/11/2019

Willow Biosciences To Commence Trading on The OTCQB® Venture Market

CALGARY, Alberta, November 5, 2019 — Willow Biosciences Inc. (“Willow” or the “Company”) (CSE:WLLW;...
29/08/2019

Willow Biosciences Reports Second Quarter 2019 Results And Provides Operations Update

Calgary, Alberta – August 29, 2019 – Willow Biosciences Inc. (“Willow” or the “Company”) (CSE:...
04/06/2019

Willow Biosciences and Noramco Announce Joint Development of Biosynthesis Platform for Cannabidiol

New activity will add options and potential for cost savings to Noramco’s robust CBD...
27/05/2019

Willow Biosciences and Tuatara Capital Announce Exercise of Warrants

CALGARY, May 27, 2019 /CNW/ – Willow Biosciences Inc. (“Willow” or the “Company“) (CSE:...
14/05/2019

Willow Biosciences Inc. Announces Share Consolidation

CALGARY, May 14, 2019 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (CSE:WLLW)...
12/04/2019

Makena Resources Inc., Biocan Technologies Inc. and Epimeron Inc. Announce Completion of Private Placement, Strategic Investment From Tuatara Capital and Business Combination to Form Willow Biosciences Inc.

VANCOUVER and CALGARY, April 12, 2019 /CNW/ – Makena Resources Inc. (“Makena“) (CSE: MKNA),...

Mountain View, CA

Focused on identifying and deploying additional genetic elements and solutions to further enhance production of our yeast strains and processes. This state-of-the-art R&D facility includes high-throughput molecular biology and screening technologies, high-end analytical instrumentation and fermentation capabilities along with systems to rapidly evaluate high volumes of data and results.